Daniel D. Von Hoff
Impact in
- Oncology top 0.01%
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 387
- Pancreatic and Hepatic Oncology Research 144
- Cancer Treatment and Pharmacology 104
- Colorectal Cancer Treatments and Studies 44
- Cancer-related Molecular Pathways 33
-
- Cancer therapeutics and mechanisms 81
- Co-authors
- Haiyong Han (73 shared papers)Howard A. Burris (49 shared papers)Mace L. Rothenberg (16 shared papers)Malcolm J. Moore (10 shared papers)M. Christine Cripps (3 shared papers)John Sahl Andersen (3 shared papers)Russell K. Portenoy (3 shared papers)Anna Maria Storniolo (3 shared papers)
- Journals
- Journal of Clinical Oncology (126 papers)Investigational New Drugs (45 papers)Cancer Research (44 papers)Molecular Cancer Therapeutics (38 papers)Annals of Oncology (32 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Daniel D. Von Hoff
808 papers receiving 43.9k citations
Daniel D. Von Hoff's Hit Papers
Peers
Comparison fields: 5 of 173
- Oncology 20.0k
- Cancer Research 6.6k
- Molecular Biology 17.9k
- Genetics 1.7k
- Pulmonary and Respiratory Medicine 4.8k
Countries citing papers authored by Daniel D. Von Hoff
This map shows the geographic impact of Daniel D. Von Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Von Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Von Hoff more than expected).
Fields of papers citing papers by Daniel D. Von Hoff
This network shows the impact of papers produced by Daniel D. Von Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Von Hoff. The network helps show where Daniel D. Von Hoff may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel D. Von Hoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 822 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Hit paper breakdown → | 1997 | 4651 |
| 2 | Risk Factors for Doxorubicin-lnduced Congestive Heart Failure Hit paper breakdown → | 1979 | 1883 |
| 3 | Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma Hit paper breakdown → | 2012 | 1616 |
| 4 | Hypersensitivity reactions from taxol. Hit paper breakdown → | 1990 | 952 |
| 5 | Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma Hit paper breakdown → | 2009 | 835 |
| 6 | Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Hit paper breakdown → | 2001 | 831 |
| 7 | Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial Hit paper breakdown → | 2011 | 830 |
| 8 | Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 Hit paper breakdown → | 2009 | 764 |
| 9 | ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Hit paper breakdown → | 1997 | 746 |
| 10 | Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Hit paper breakdown → | 1990 | 660 |
| 11 | nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial Hit paper breakdown → | 2015 | 510 |
| 12 | 2007 | 484 | |
| 13 | Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer Hit paper breakdown → | 2015 | 481 |
| 14 | 2009 | 467 | |
| 15 | 1996 | 454 | |
| 16 | 2010 | 444 | |
| 17 | 2011 | 423 | |
| 18 | 2014 | 418 | |
| 19 | 1999 | 414 | |
| 20 | Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations Hit paper breakdown → | 2014 | 386 |
About Daniel D. Von Hoff
Daniel D. Von Hoff is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Epidemiology, having authored 822 papers that have together received 45.3k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (144 papers), Cancer Treatment and Pharmacology (104 papers), Cancer Genomics and Diagnostics (88 papers), Cancer therapeutics and mechanisms (81 papers), Colorectal Cancer Treatments and Studies (44 papers), Lung Cancer Treatments and Mutations (37 papers), Cancer-related Molecular Pathways (33 papers) and Cancer, Hypoxia, and Metabolism (31 papers). The work is most often cited by research in Oncology (20.0k citations), Cancer Research (6.6k citations), Molecular Biology (17.9k citations), Genetics (1.7k citations) and Pulmonary and Respiratory Medicine (4.8k citations). Daniel D. Von Hoff has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Haiyong Han, Howard A. Burris, Mace L. Rothenberg, Malcolm J. Moore, M. Christine Cripps, John Sahl Andersen, Russell K. Portenoy, Anna Maria Storniolo, Peter G. Tarassoff and F. Andrew Dorr. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer Research, Molecular Cancer Therapeutics and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.